Skip to main content

Advertisement

ADVERTISEMENT

Department

News Connection
01/28/2019
Bill De Blasio, mayor of New York City, is expected to unveil a new health plan for all city residents that will guarantee care regardless of their ability to pay or their immigration status.
Bill De Blasio, mayor of New York City, is expected to unveil a new health plan for all city residents that will guarantee care regardless of their ability to pay or their immigration status.
Bill De Blasio, mayor of New...
01/28/2019
First Report Managed Care

Advertisement

News Connection
01/28/2019
In a recent press release, Pfizer Inc and GlaxoSmithKline plc (GSK) announced they have entered into an agreement to create a premier global consumer health care company.
In a recent press release, Pfizer Inc and GlaxoSmithKline plc (GSK) announced they have entered into an agreement to create a premier global consumer health care company.
In a recent press release,...
01/28/2019
First Report Managed Care
News Connection
01/28/2019
Walgreens Boots Alliance, Inc and Verily, an Alphabet company, have announced they will collaborate on multiple projects in a new partnership. Under a broad agreement, the companies will work to improve health outcomes for patients with...
Walgreens Boots Alliance, Inc and Verily, an Alphabet company, have announced they will collaborate on multiple projects in a new partnership. Under a broad agreement, the companies will work to improve health outcomes for patients with...
Walgreens Boots Alliance, Inc...
01/28/2019
First Report Managed Care
News Connection
01/28/2019
Bristol-Myers Squibb has announced it will buy Celgene and create a leading specialty biopharma company. The cash and stock deal is valued at $74 billion. 
Bristol-Myers Squibb has announced it will buy Celgene and create a leading specialty biopharma company. The cash and stock deal is valued at $74 billion. 
Bristol-Myers Squibb has...
01/28/2019
First Report Managed Care

Advertisement

Conference Insider
01/28/2019
A study presented at ASHP 2018 Midyear Clinical Meeting & Exhibition compared the cost-effectiveness of betrixaban to enoxaparin in patients presenting with venous thromboembolism (VTE.) 
A study presented at ASHP 2018 Midyear Clinical Meeting & Exhibition compared the cost-effectiveness of betrixaban to enoxaparin in patients presenting with venous thromboembolism (VTE.) 
A study presented at ASHP 2018...
01/28/2019
First Report Managed Care
Conference Insider
01/28/2019
A presentation at ASHP 2018 Midyear Clinical Meeting & Exhibition showed success in tracking operative clinical progress, opiod use and pain scores, and chronic postsurgal pain risk factors in veterans by utilizing new health information...
A presentation at ASHP 2018 Midyear Clinical Meeting & Exhibition showed success in tracking operative clinical progress, opiod use and pain scores, and chronic postsurgal pain risk factors in veterans by utilizing new health information...
A presentation at ASHP 2018...
01/28/2019
First Report Managed Care
Conference Insider
01/28/2019
An evaluative study presented at the ASHP 2018 Midyear Clinical Meeting & Exhibition explained ways one hospital combats drug shortages using preventive measures.
An evaluative study presented at the ASHP 2018 Midyear Clinical Meeting & Exhibition explained ways one hospital combats drug shortages using preventive measures.
An evaluative study presented at...
01/28/2019
First Report Managed Care

Advertisement

Conference Insider
01/28/2019
A study presented at ASH Annual Meeting 2018 would suggest that ibrutinib is a strong option for patients aged 65 and older in the prevention of relapse in patients with chronic lymphocytic leukemia (CLL).
A study presented at ASH Annual Meeting 2018 would suggest that ibrutinib is a strong option for patients aged 65 and older in the prevention of relapse in patients with chronic lymphocytic leukemia (CLL).
A study presented at ASH Annual...
01/28/2019
First Report Managed Care
Conference Insider
01/28/2019
In a study presented at the ASH Annual Meeting 2018 in San Diego, researchers asked, “Are patients willing to trade off efficacy for tolerability?” in reference to the treatment of relapsed/refractory multiple myeloma (RRMM). 
In a study presented at the ASH Annual Meeting 2018 in San Diego, researchers asked, “Are patients willing to trade off efficacy for tolerability?” in reference to the treatment of relapsed/refractory multiple myeloma (RRMM). 
In a study presented at the ASH...
01/28/2019
First Report Managed Care
Conference Insider
01/28/2019
Researchers at the ASH Annual Meeting 2018 in San Diego presented that young adult patients diagnosed with accute lymphoblastic leukemia (ALL) being treated at specialized cancer centers (SCCs) are spending more for inpatient care and...
Researchers at the ASH Annual Meeting 2018 in San Diego presented that young adult patients diagnosed with accute lymphoblastic leukemia (ALL) being treated at specialized cancer centers (SCCs) are spending more for inpatient care and...
Researchers at the ASH Annual...
01/28/2019
First Report Managed Care

Advertisement

Advertisement